Wolverine Trading
APLS

Wolverine Trading’s Apellis Pharmaceuticals APLS Stock Holding History

Wolverine Trading’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$328K Sell
14,480
-1,718
-11% -$40.1K ﹤0.01% 4254
2025
Q2 		$282K Buy
16,198
+2,770
+21% +$51.3K ﹤0.01% 3543
2025
Q1 		$326K Buy
13,428
+2,852
+27% +$78.8K ﹤0.01% 3432
2024
Q4 		$337K Sell
10,576
-2,622
-20% -$78.8K ﹤0.01% 3885
2024
Q3 		$389K Buy
13,198
+3,982
+43% +$147K ﹤0.01% 3322
2024
Q2 		$354K Sell
9,216
-3,082
-25% -$140K ﹤0.01% 3194
2024
Q1 		$723K Buy
12,298
+5,579
+83% +$356K ﹤0.01% 2500
2023
Q4 		$402K Sell
6,719
-15,655
-70% -$794K ﹤0.01% 3174
2023
Q3 		$851K Buy
+22,374
New +$983K ﹤0.01% 2246
2023
Q2 		– Sell
-5,966
Closed -$515K – 4206
2023
Q1 		$394K Buy
+5,966
New +$344K ﹤0.01% 2741
2021
Q4 		– Sell
-33,143
Closed -$1.3M – 5722
2021
Q3 		$1.13M Buy
+33,143
New +$1.86M ﹤0.01% 2842

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wolverine Trading's APLS Position: Q3 2025 in Review

Wolverine Trading reduced its Apellis Pharmaceuticals (APLS) stake by 11% in Q3 2025, selling an estimated $40.1K and leaving 14,480 shares worth $328K. The position accounts for ﹤0.01% of the portfolio, ranked #4254.

Wolverine Trading first reported a position in APLS in Q3 2021 and has held it in 11 quarters since. The position peaked at $1.13M in Q3 2021. 273 funds tracked by Wall St. Rank hold APLS as of Q3 2025.

  • Wolverine Trading held 14,480 shares of Apellis Pharmaceuticals worth $328K as of Q3 2025.
  • Wolverine Trading sold 1,718 Apellis Pharmaceuticals shares in Q3 2025, an estimated $40.1K.
  • Apellis Pharmaceuticals made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #4254 holding.
  • Wolverine Trading first reported a position in Apellis Pharmaceuticals in Q3 2021 and has held it in 11 quarters since.
  • Wolverine Trading's Apellis Pharmaceuticals position peaked at $1.13M in Q3 2021.
  • 273 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.